Introduction
============

Chronic obstructive pulmonary disease (COPD) has become a principal international health problem with a rise in prevalence and mortality ([@b1-mmr-18-03-3143]), as there was a 44.2% increase of the number of prevalent COPD cases between 1990 and 2015 ([@b2-mmr-18-03-3143]). The most common symptoms of COPD include, chronic cough, expectoration, shortness of breath and difficulty in breathing ([@b3-mmr-18-03-3143]). COPD is generally considered to be an abnormal inflammatory disorder leading to airflow limitation associated with the response of lungs to toxic and noxious particles, and gases, and is primarily caused by tobacco smoking ([@b4-mmr-18-03-3143]). Inflammation, oxidative stress and imbalance between levels of proteinases and antiproteinases within the lungs are also the predisposing factors to COPD ([@b5-mmr-18-03-3143]).

The pathological alterations may be identified in the large airways, small airways, lung parenchyma and pulmonary vascular of patients with COPD ([@b6-mmr-18-03-3143]--[@b8-mmr-18-03-3143]). Multiple alterations in the airway are closely associated with COPD, and the symptoms are similar to vascular remodeling in patients with atherosclerosis ([@b9-mmr-18-03-3143]). Airway wall has been demonstrated to be thickened in patients with COPD, primarily as a result of hyperplasia and hypertrophy of airway smooth muscle cells (ASMCs) and accumulation of extracellular matrix (ECM) components ([@b10-mmr-18-03-3143]). The ECM of the lung consists of a number of macromolecules, including collagens, fibronectin, laminin (LN), proteoglycans, glycosaminoglycan, elastin and tenascin, which form a complex, dynamic network ([@b11-mmr-18-03-3143],[@b12-mmr-18-03-3143]). In patients with COPD, the levels of elastin ([@b13-mmr-18-03-3143]) and proteoglycans ([@b14-mmr-18-03-3143]) were deceased, while LN and total collagen content were elevated ([@b15-mmr-18-03-3143]). Collagen I (COL-1) and collagen-III (COL-3) are two types of lung interstitium components that serve a role in establishing normal lung architecture ([@b16-mmr-18-03-3143]). LN has been reported to be the primary component of basement membranes and to regulate cell behavior in bronchiolar epithelium of patients with COPD ([@b17-mmr-18-03-3143]). Furthermore, ECM proteins are associated with biological properties of human ASMCs including growth, survival, migration and adhesion ([@b12-mmr-18-03-3143]). To date, a limited number of studies investigating the role of deposition of COL-1, COL-3 and LN on the biological behavior of ASMCs in patients with COPD. Airway smooth muscle (ASM) preserves the dynamic homeostasis of synthesis/degradation of ECM though secretion of various ECM proteins, including matrix metalloproteinases (MMPs) ([@b18-mmr-18-03-3143]), tissue inhibitors of metalloproteinases (TIMPs) ([@b19-mmr-18-03-3143]), cytokines ([@b12-mmr-18-03-3143]), chemokines ([@b12-mmr-18-03-3143]) and growth factors ([@b20-mmr-18-03-3143]). Evidence accumulated from previous studies indicated that ECM proteins are implicated directly or indirectly in multiple signaling pathways to influence various biological processes ([@b21-mmr-18-03-3143]--[@b23-mmr-18-03-3143]). Khatiwala *et al* ([@b24-mmr-18-03-3143]) demonstrated that ECM modulates the mitogen-activated protein kinase signaling pathway and acts downstream of transforming protein RhoA and Rho-associated protein kinase 1 for the regulation of osteogenesis. In a previous study, COL-1 was associated with morphological alterations of mouse NMuMG cells and upregulation of cadherin-2 though the phosphoinositide 3-kinase (PI3K)-Rac1-JNK pathway ([@b24-mmr-18-03-3143]). Integrin α6β1 and FAK-MEK/ERK signaling promote mesenchymal stem cell growth induced by LN-1 under growth factors in the absence of serum and differentiation factors ([@b25-mmr-18-03-3143]). However, few studies have evaluated the association between ECM proteins and signaling pathways in the airways of patients with COPD.

In the present study, a rat model of COPD was established to assess the impact of ECM components (COL-1, COL-3 and LN) on proliferation, migration and attachment of ASMCs. Cytokines, chemokines, growth factors, MMP-9 and its inhibitor, TIMP1, were detected. The molecular signaling that may be involved the thickening of airway wall was further elucidated.

Materials and methods
=====================

### COPD animal model construction

A total of 24 healthy male Sprague Dawley (SD; 10--12 weeks; 180--220 g; five per cage) rats were purchased from Shanghai Laboratory Animal Research Center (Shanghai, China) and housed in the animal room (25±3°C; 50% humidity; 12/12 h light and dark cycle) with free access to water and food. The rat model of COPD was established as described in previous studies ([@b26-mmr-18-03-3143]--[@b28-mmr-18-03-3143]). Briefly, 12 SD rats were anesthetized with 0.45% pentobarbital sodium (50 mg/kg) via intraperitoneal injection, followed by injection of lipopolysaccharide (LPS; 200 mg/200 µl) through the trachea and inhalation of fresh smoke once a day for 30 days, then kept at −20°C for 5 min/day for the next 30 days to establish animal models of COPD. The remaining 12 rats served as the normal group and received no treatment. All experimental protocols were approved by the Animal Research Committee of Hubei University of Medicine (Suizhou, China). The care and use of animals was based on the Guidelines by the National Institutes of Health.

### Isolation of rat airway smooth muscle cells (ASMCs)

Rat ASMCs were isolated as described in previous studies ([@b29-mmr-18-03-3143]--[@b31-mmr-18-03-3143]). Briefly, entire rat tracheae were rapidly dissected from normal and COPD rats in ice-cold PBS solution. Subsequently, the mucosal and connective tissues were removed and muscle was gently separated in small bundles. Separated muscle was placed in Ham\'s F12 digestion solution containing 0.5% fetal bovine serum (FBS; cat. no. 16000-044; Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA) supplemented with collagenase IV (2 mg/ml; Sigma-Aldrich; Merck KGaA, Darmstadt, Germany) and papain (1 mg/ml; Sigma-Aldrich; Merck KGaA). Following centrifugation at 500 × g for 15 min at 4°C, cell suspension was collected and isolated ASMCs were treated with 0.25% trypsin and cells from passages 3--5 were selected for the subsequent experiments.

### Cell culture and treatment

All ASMCs were maintained in Ham\'s F12 medium (cat. no. A1526_9010; AppliChem, Inc., St. Louis, MO, USA) with 10% FBS in a humidified atmosphere containing 5% CO~2~ at 37°C. For cell functional analysis, ASMCs were seeded in 24-well plates and each well was treated with 500 µl ECM components, including COL-1 \[cat. no. CLS001654; Sangon Biotech (Shanghai) Co., Ltd., Shanghai, China\], LN (cat. no. L4544; Sigma-Aldrich; Merck KGaA) or COL-3 (cat. no. ab7535; Abcam, Cambridge, UK) at a concentration of 10 mg/l each, except for the blank control cells, which were treated with 500 µl bovine serum albumin (BSA; 10 ml/l; cat. no. A8020; Beijing Solarbio Science & Technology Co., Ltd., Beijing, China) in a humidified atmosphere containing 5% CO~2~ at 37°C for 2 h.

### Immunofluorescence (IF)

The morphology of the isolated ASMCs was assessed by IF staining. Briefly, ASMCs at a density of 10^6^ were washed twice with PBS and fixed with 4% paraformaldehyde for 10 min at room temperature. The cells were subsequently treated with pre-cooled 100% methanol for 20 min at −20°C and subsequently blocked in PBS containing 3% BSA for 1 h at room temperature. The cells were then incubated with α-smooth muscle actin (α-SMA) mouse primary antibody (1:200; Abcam; cat. no. ab8211) at 4°C overnight, followed by incubation with Alexa Fluor 647 (red)-conjugated secondary antibody (1:500; cat. no. Z25008; Invitrogen; Thermo Fisher Scientific, Inc.) at 37°C for 30 min in the dark. DAPI (100 ng/ml; Invitrogen; Thermo Fisher Scientific, Inc.) was used to stain the nuclei (10 min at room temperature). Finally, the location of α-SMA was detected using a laser scanning confocal microscope (LSM 710; Carl Zeiss AG, Oberkochen, Germany).

### Cell Counting kit-8 (CCK-8) assay

The proliferation of ASMCs was determined by CCK-8 assay (cat. no. C0037; Beyotime Institute of Biotechnology, Haimen, China). Briefly, cells were seeded into 96-well plates at a density of 3×10^4^ cells/well. Following different treatments, the supernatant was removed and 10 µl CCK-8 solution was added to each well at 24, 48 or 72 h, and the mixture was incubated for 1 h at 37°C. The absorbance was measured at a wavelength of 450 nm using a microplate reader (Bio-Rad Laboratories, Inc., Hercules, CA, USA). The experiment was repeated three times.

### 5-Ethynyl-2′-deoxyuridine (EdU) proliferation analysis

Following different treatments, ASMCs (10^5^ cells/well) were seeded in triplicate in 96-well plates and their proliferation was measured using the Cell-Light EdU DNA Cell Proliferation kit (Guangzhou RiboBio Co., Ltd., Guangzhou, China) according to the manufacturer\'s protocol. In brief, cells were treated with 50 mM EdU for 4 h at 37°C and fixed with 4% formaldehyde for 15 min at room temperature. Subsequently cells were incubated with 100 µl Apollo reaction cocktail for 30 min at room temperature and stained with DAPI (50 ng/ml) at room temperature for 30 min. The images of stained cells were observed using a fluorescent microscope (Olympus Corporation, Tokyo, Japan; magnification, ×120). Each sample was analyzed in triplicate in three independent experiments. The experiment was repeated three times.

### Cell cycle detection

ASMCs (10^5^ cell/well) were treated with 0.25% trypsin and seeded into 24-well plates at a density of 5×10^5^ cells/well. Following washing with PBS, cells were fixed with 75% ethanol at room temperature for 24 h, washed again with PBS and stained with 100 ng/ml propidium iodide for 30 min at room temperature (BD Biosciences, San Jose, CA, USA). Subsequently, cell cycle analysis was performed on FACSCalibur flow cytometer (BD Biosciences). Cell Quest software 1.1 (BD Biosciences) was used to calculate the percentage of cell population in each phase, including G~0~/G~1~, S and G~2~/M.

### Wound healing analysis

The ASMCs (10^5^ cells/well) were incubated overnight following treatment with different ECM components until grown to \~90% confluence. On the following day, a standard 200 µl plastic filter tip was drawn across the well to produce a wound to evaluate the directional motility of cells. The wound areas were observed and images were captured at 0 and 48 h with a fluorescent microscope under bright field illumination (Axio Observer A1; Zeiss AG, Oberkochen, Germany; magnification, ×4). The wound healing effect was determined by calculating the radio of the wound area to the total area using ImageJ bundled with Java 1.8.0_112 (National Institutes of Health, Bethesda, MD, USA). The degree of wound closure was analyzed in three randomly selected fields of view. The experiment was repeated three times.

### Cell adhesion assay

Following different treatments, ASMCs were trypsinized and seeded at a density of 5×10^4^ cells/well on Matrigel-precoated 96-well culture plates. The cells were incubated for 2 h at 37°C and non-adherent cells were removed by washing with PBS. Cells were fixed with 4% paraformaldehyde at 4°C for 24 h, followed by 0.5% toluidine blue staining for 20 min at room temperature and 1% sodium dodecyl sulfate (2 h at room temperature). The optical density values were determined using a microplate reader (Bio-Rad Laboratories, Inc.) at a wavelength of 595 nm. The experiment was repeated two times.

### ELISA

The supernatants were collected from ASMCs following treatment with different ECM components. The levels of total MMP-9, C-X-C motif chemokine ligand 1 (CXCL1), C-X-C motif chemokine ligand 8 (CXCL8) and interleukin-6 (IL-6) in the supernatants were measured using MMP-9 ELISA kit (cat. no. CSB-E08008r), CXCL1 ELISA kit (cat. no. CSB-E12997r), CXCL8 ELISA kit (cat. no. ml002885) and IL-6 ELISA kit (cat. no. CSB-E04640r), according to the manufacturer\'s protocols (all Cusabio Technology, LLC, College Park, MD, USA). The concentrations are expressed in pg/ml. The experiment was repeated three times.

### RNA extraction and reverse transcription-quantitative polymerase chain reaction (RT-qPCR)

Total RNA was extracted from ASMCs using TRIzol^®^ reagent (Invitrogen; Thermo Fisher Scientific, Inc.) and reverse transcribed into cDNA using the PrimeScript RT Reagent kit (Takara Bio, Inc., Otsu, Japan), according to the manufacturer\'s protocol. The RT-qPCR reactions were performed using ABI7500 real-time RCR System (Applied Biosystems; Thermo Fisher Scientific, Inc.). SYBR-Green Master Mix kit and the following thermocycling conditions were used for qPCR: 30 cycles of 30 sec at 94°C, 30 sec at 55°C and 30 sec at 72°C. The following primer sequences were used for PCR: MMP-9 forward, 5′-TCATCCAGTTTGGTGTCGC-3′ and reverse, 5′-AGTGGGCATCTCCCTGAAT-3′; TIMP1 forward, 5′-GCCTCTGGCATCCTCTTG-3′ and reverse, 5′-CTGCGGTTCTGGGACTTG-3′; transforming growth factor β-1 (TGFβ1) forward, 5′-AGGCGGTGCTCGCTTTG-3′ and reverse, 5′-TGCGTTGTTGCGGTCCA-3′; fibroblast growth factor 1 (FGF-1) forward, 5′-GATGGCACAGTGGATGGGAC-3′ and reverse, 5′-AAGCCCGTCGGTGTCCATGG-3′; and GAPDH forward, 5′-CCTCGTCTCATAGACAAGATGGT-3′ and reverse, 5′-GGGTAGAGTCATACTGGAACATG-3′. The fold-change in the expression of each target mRNA relative to GAPDH was calculated using the 2^−ΔΔCq^ method ([@b32-mmr-18-03-3143]).

### Western blot analysis

All ASMCs (10^6^) were lysed in 120 µl radioimmunoprecipitation assay lysis buffer (cat. no. P0013B; Beyotime Institute of Biotechnology) with phosphatase and protease inhibitors (BIOSS, Beijing, China) for 2 h at 4°C. Following protein quantitation using a bicinchoninic acid protein assay kit (Thermo Fisher Scientific, Inc.), proteins (30 µg/lane) were separated by 10% SDS-PAGE and transferred to polyvinylidene fluoride membranes. Following blocking with 5% non-fat milk for 1 h at room temperature, the membranes were incubated at 4°C overnight with primary antibodies, including anti-TGFβ1 (1:800; cat. no. bs-0086R; BIOSS), anti-FGF-1 (1:800; cat. no. 10-P1311-1; American Research Specialty Products; Palos Verdes Estates, CA, USA), anti-MMP-9 (1:800; cat. no. 10-P1357-1; American Research Specialty Products), anti-TIMP1 (1:800; cat. no. 28-60319P; American Research Specialty Products), anti-PI3K (1:800; cat. no. 05-212-K; Merck KGaA), anti-p (phosphorylated)-RAC-α serine/threonine-protein kinase (AKT; 1:800; cat. no. 28101-025; AnaSpec; Eurogentec, Liège, Belgium), anti-p-serine/threonine-protein kinase mTOR (mTOR; 1:800; cat. no. BS4706; Bioworld Technology, Inc., St. Louis Park, MN, USA), anti-AKT (1:800; cat. no. MA514916; Thermo Fisher Scientific, Inc.), anti-mTOR (1:800; cat. no. 17-18594; American Research Specialty Products) and anti-GAPDH (1:800; cat. no. sc-47724; Santa Cruz Biotechnology, Inc., Dallas, TX, USA), followed by incubation with horseradish peroxidase-conjugated goat anti-mouse secondary antibody (1:2,000; cat. no. A12000-1; Epigentek Group, Inc., Farmingdale, NY, USA) for 1 h at room temperature. The protein bands were detected using a Chemiluminescence Exposure Screen kit (cat. no. 62242; Pierce; Thermo Fisher Scientific, Inc.). The experiment was repeated three times.

### Signal transduction pathways

COL-3-mediated adhesion and migration of ASMC was studied using specific pharmacological antagonists of PI3K. The PI3K inhibitor LY294002 (500 nM; cat. no. S1105; Selleck Chemicals, Houston, TX, USA) and activator insulin-like growth factor-1 (50 mM; IGF-1; Sigma-Aldrich; Merck KGaA) were added to the COPD ASMCs 30 min prior to the addition of COL-3 and remained in contact with the cells for the duration of the present study. The experiment was repeated three times.

### Statistical analysis

All data are presented as the mean ± standard deviation. The differences between groups were analyzed using GraphPad Prism (version 7; GraphPad Software, Inc., La Jolla, CA, USA) using one-way analysis of variance with Tukey\'s post hoc test. P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### ECM components promote cell proliferation and cell cycle progression of ASMCs

ASMC were successfully isolated from normal and COPD rats. Following inoculation of ASMC into culture plates at 37°C for 3 days, the cells presented spindle shape (round centered nuclei). Subsequently, the expression of α-SMA in normal and COPD rat ASMCs was determined by IF. The ASMCs exhibited abundant expression of α-SMA ([Fig. 1](#f1-mmr-18-03-3143){ref-type="fig"}) indicating that ASMCs were isolated in high purity. To determine the role of ECM components in proliferative kinetics of ASMCs, a CCK-8 assay was performed to determine cell proliferation ability of ASMCs. COL-1 and COL-3 significantly promoted proliferation of control and COPD ASMCs (P\<0.05; [Fig. 2A](#f2-mmr-18-03-3143){ref-type="fig"}), while LN exhibited no significant effect on cell proliferation ability. The percentage of cells in S phase was significantly increased following treatment of normal and COPD ASMCs with COL-1 and COL-3 compared with the respective control groups (P\<0.05 and P\<0.01; [Fig. 2B](#f2-mmr-18-03-3143){ref-type="fig"}). Representative histograms of cell cycle distribution are presented in [Fig. 2C](#f2-mmr-18-03-3143){ref-type="fig"}. Promotion of cell cycle progression induced by ECM components was more significant in ASMCs derived from COPD rats compared with normal ASMCs.

### ECM components promote migration and adhesion of ASMCs

Wound-healing assay was performed to determine the effect of ECM components on cell migration ability. Deceleration in the wound closure rate was observed in ASMCs derived from normal rats following treatment with ECM components compared with the control group (P\<0.01, P\<0.001; [Fig. 3A and B](#f3-mmr-18-03-3143){ref-type="fig"}). Treatment with COL-1 and COL-3 significantly elevated cell migration ability of ASMCs derived from rats with COPD. Furthermore, adhesion ability of ASMCs was assessed by cell adhesion assay. The results indicated that the adhesive ability of ASMCs was stronger in groups treated with ECM components compared with the control cells in normal ASMCs and COPD ASMCs (P\<0.05 and P\<0.01; [Fig. 3C](#f3-mmr-18-03-3143){ref-type="fig"}).

### Effect of ECM components on factors associated with inflammation, growth and migration of ASMCs

It is widely accepted that inflammation serves a critical role in the pathogenesis of COPD ([@b33-mmr-18-03-3143],[@b34-mmr-18-03-3143]). Expression levels of factors associated with inflammation were determined using ELISA. ECM components, including COL-1, LN and COL-3, altered the levels of CXCL1, CXCL8 and IL-6 in ASMCs derived from normal rats ([Fig. 4A](#f4-mmr-18-03-3143){ref-type="fig"}) and rat models of COPD ([Fig. 4B](#f4-mmr-18-03-3143){ref-type="fig"}). Expression of factors associated with growth and migration in ASMCs was also determined by RT-qPCR and western blotting assays. The results indicated that expression levels of TGFβ1 and FGF-1, both associated with cell growth, were significantly elevated following treatment with ECM components in ASMCs from normal rats and COPD model rats ([Fig. 5](#f5-mmr-18-03-3143){ref-type="fig"}). Consistent with the promoted cell migration ability, treatment with ECM components markedly decreased expression of MMP-9 and increased expression of TIMP1 in ASMCs derived from normal rats and rat models of COPD. The above data suggests that ECM may promote inflammation, proliferation and migration ability of ASMCs.

### Effects of ECM components of ASMCs in rat models of COPD are mediated by the PI3K/AKT signaling pathway

PI3K is a signaling pathway associated with cell proliferation and migration ([@b35-mmr-18-03-3143],[@b36-mmr-18-03-3143]). Based on the above results, which indicated that ECM components promoted migration and adhesion of ASMCs, the subsequent experiments aimed to determine whether PI3K signaling pathway mediated the effects of the ECM components. The above results indicated that COL-3 was more efficient at promoting cell proliferation and migration, compared with COL-1 and LN. Therefore, COL-3-mediated promotion of adhesion and migration of ASMCs was studied using specific PI3K inhibitor LY294002 or activator IGF-1. As demonstrated in [Fig. 6A](#f6-mmr-18-03-3143){ref-type="fig"}, incubation of ASMCs form rat models of COPD with COL-3 and IGF-1 increased the proportion of EdU-positive cells, compared with cells incubated with COL-3 only, indicating enhanced cell proliferation. By contrast, incubation with COL-3 and LY294002 resulted in the opposite effect. In the cell cycle assay, treatment with IGF1 significantly reduced the percentage of cells in G~0~/G~1~ phase and increased the percentage of cells in S phase. The opposite was the case following incubation with LY294002 ([Fig. 6B](#f6-mmr-18-03-3143){ref-type="fig"}). Furthermore, cell migration ability was enhanced by incubation with IGF-1 and impaired following treatment with LY294002 in ASMCs derived from rat models of COPD ([Fig. 7A and B](#f7-mmr-18-03-3143){ref-type="fig"}; P\<0.01). At the molecular level, western blot analysis confirmed that treatment with IGF1 markedly elevated the level of TGFβ1, FGF-1, TIMP1, PI3K, p-AKT and p-mTOR, and decreased the expression of MMP-9 ([Fig. 7C](#f7-mmr-18-03-3143){ref-type="fig"}). Consistently, treatment with LY294002 induced the opposite effects on these molecules. These results further demonstrated that the effects of ECM components on ASMCs are associated with the activation of the PI3K signaling pathway.

Discussion
==========

COPD is a disorder typically caused by inhalation of toxic gases and particles, which leads to impairments of lung function, including emphysema, chronic bronchitis, mucus production and irreversible airway obstruction ([@b37-mmr-18-03-3143]). Alteration of ECM deposition is a characteristic of COPD and provides a suitable environment for airway wall remodeling, especially airway wall thickening ([@b18-mmr-18-03-3143]). The present study aimed to determine the response of ASMCs to the accumulation of components of ECM, including COL-1, COL-3 or LN. COL-1 and COL-3 markedly increased proliferation of ASMCs, whereas no alterations were detected in cells treated with LN, indicating that the proliferative response of ASMCs varied depending exposure to different components of ECM. Consistently, the present study revealed similar results to previous studies; components of ECM differentially affected proliferation of vascular smooth muscle cells in cell culture studies ([@b38-mmr-18-03-3143],[@b39-mmr-18-03-3143]). Following treatment with COL-1 and COL-3, there was an increased percentage of ASMCs in the S phase. Migration of cells is controlled by multiple stages, including extension of the lamellipodium, formation of new adhesions and retraction of protrusions ([@b40-mmr-18-03-3143]). Correct modulation of adhesion and de-adhesion are necessary for cell migration ([@b40-mmr-18-03-3143]). In the present study, migratory responses to treatment with ECM substrates were estimated using a wound-healing assay. Culture dishes treated with COL-1, COL-3 or LN exhibited relatively decreased wound area in ASMCs from normal rats and rat models of COPD, compared with the respective controls. The data suggests that these three ECM components promote migration of ASMCs in culture. Compared with the control, ASMCs from normal rats and the COPD model exhibited enhanced attachment following stimulation with COL-1, LN or COL-3, compared with the control. Increased cell adhesion may contribute to migration of ASMCs induced by treatment with COL-1, COL-3 or LN.

COPD results in aberrant thickening of generalized airway walls, particularly in smokers, with airway walls thickened throughout the lung ([@b41-mmr-18-03-3143]). Hyperplasia and hypertrophy of the smooth muscle are associated with the pathology of COPD ([@b42-mmr-18-03-3143]). Induction of proliferation, migration and attachment by ECM components in the present study lead to investigation of the effects on cytokines, growth factors, MMPs, TIMPs and chemokines synthesized by ASMCs. The level of MMP-9 was downregulated, while the concentration of its inhibitor TIMP1 was upregulated in ASMCs from normal rats and the COPD model rats following treatment with the ECM molecules. Previous studies demonstrated that the activated and precursor forms of MMP-9 may bind to its inhibitor TIMP-1 to form a complex, thus the ratio of MMP-9 and TIMP-1 is closely associated with the degradation and accumulation ECM ([@b43-mmr-18-03-3143]). An increased TIMP-1/MMP-9 ratio facilitates TGFβ1 induced synthesis of ECM substrates, including COL-1, COL-2, COL-5 and fibronectin in human ASMCs. Furthermore, TGFβ has been demonstrated to promote expression of certain other ECM proteins, including perlecan, elastin, LN, COL-3, COL-4 and thrombospondin ([@b18-mmr-18-03-3143],[@b44-mmr-18-03-3143]). In the present study, mRNA and protein expression levels of TGFβ1 were evaluated following treatment with COL-1, COL-3 or LN, thus it was suggested that TGFβ1 induced over production of multiple ECM proteins in ASMCs in COPD rats. The results of the present study suggest that there may be an association between ECM and TGFβ1 in rats. Cell proliferation and migration are promoted by ECM proteins ([@b12-mmr-18-03-3143]). In the cells treated with COL-1, COL-3 and LN, an upregulation of TGFβ1 and alteration of ECM was identified, which may result in ASMC hyperplasia and migration.

It has been previously reported that cytokines, chemokines and growth factors may influence the secretion of ECM proteins by ASMCs and therefore impact biological behavior of ASMCs ([@b12-mmr-18-03-3143]). ECM proteins are considered to promote production of cytokines and chemokines by ASMCs, which are associated with the development of COPD pathophysiology ([@b12-mmr-18-03-3143]). In the present study, the pro-inflammatory chemokines CXCL1 and CXCL8, cytokine IL-6, and FGF-1 were increased in ASMCs by treatment with ECM molecules. The imbalance in ECM homeostasis causes hyper proliferative and migratory phenotypes in ASMCs.

PI3K is a signaling pathway associated with proliferation and migration of ASMCs ([@b45-mmr-18-03-3143],[@b46-mmr-18-03-3143]). Incubation of rat ASMCs with PI3K agonist IGF-1 induced progression to S-phase and enhanced migration, whereas the opposite effect was observed following treatment with PI3K inhibitor LY294002. Protein expression levels of PI3K, p-AKT and p-mTOR, which have roles in PI3K signaling, were upregulated by treatment with IGF-1 and decreased following treatment with LY294002. These results indicate that activation of the PI3K signaling promotes proliferation and migration of ASMCs. Additionally, protein expression levels of TGFβ1, FGF-1 and TIMP1 were upregulated by treatment of IGF-1, while the effect was reversed by treatment with LY294002. Stewart *et al* ([@b47-mmr-18-03-3143]) demonstrated that FGFs can stimulate the PI3K signaling pathway to induce proliferation of ASMCs in COPD. In addition, TGF and collagen proteins also regulate the PI3K signaling pathway in human ASMCs ([@b48-mmr-18-03-3143]). Following treatment with IGF-1, alterations in the levels of TGFβ1, FGF-1, MMP-9 and TIMP1 may result in ECM imbalance, and the PI3K signaling may be activated by TGFβ1 and FGF-1, leading to induction of proliferation and migration.

In conclusion, the present study demonstrated that COL-1, COL-3 and LN are effective stimulators of proliferation, migration and attachment of rat AMSCs. Treatment with ECM components enhanced the expression of factors associated with inflammation, growth and migration. COL-3 induced proliferation, migration and progression to S-phase in ASMCs, partially though activation of the PI3K signaling pathway. The present study may contribute to further understanding of the molecular mechanisms underlying the COPD airway wall thickening.
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![*In vitro* culture and identification of normal ASMCs. Immunofluorescence ASMCs were spindle-shaped and grew vigorously. The expression of α-SMA was demonstrated by red fluorescence within the ASMCs. DAPI was used to stain the nuclei of the cells (blue fluorescence). Magnification, ×120. ASMCs, airway smooth muscle cells; α-SMA, α-smooth muscle actin.](MMR-18-03-3143-g00){#f1-mmr-18-03-3143}

![Effects of ECM components on proliferation and cell cycle progression of ASMCs. (A) Cell proliferation was determined in ASMCs from normal rats and rat models of COPD using Cell Counting kit-8 assay following treatment with ECM components, including COL-1, LN and COL-3. (B) Statistical analysis of cell cycle distribution of ASMCs from normal rats and rat models of COPD, following treatment with ECM components. (C) Flow cytometry was used to analyze cell cycle in ASMCs form normal rats and from rat models of COPD. Data are presented as the mean ± standard deviation in triplicate. \*P\<0.05 and \*\*P\<0.01 vs. the control group. ^\#^P\<0.05 vs. the control group at 72 h time point. ECM, extracellular matrix; ASMCs, airway smooth muscle cells; COL, collagen; LN, laminin; OD, optical density; COPD, chronic obstructive pulmonary disease.](MMR-18-03-3143-g01){#f2-mmr-18-03-3143}

![Effects of ECM components on migration and adhesion of ASMCs. Wound-healing assay was used to evaluate motility of ASMCs following treatments ECM components, including COL-1, LN and COL-3 in normal rat ASMCs and ASMCs form rat models of COPD. The wound area was (A) visualized and (B) calculated at 0 and 48 h. (C) Cell adhesion assay was performed in ASMCs following treatment with COL-1, LN and COL-3. Data are presented as the mean ± standard deviation in triplicate. \*P\<0.05, \*\*P\<0.01 and \*\*\*P\<0.001 vs. the control group. ECM, extracellular matrix; COL, collagen; LN, laminin; ASMCs, airway smooth muscle cells; COPD, chronic obstructive pulmonary disease; OD, optical density.](MMR-18-03-3143-g02){#f3-mmr-18-03-3143}

![Effects of ECM components on cytokines in ASMCs. The expression of MMP-9, CXCL1, CXCL8 and IL-6 was determined following treatment with ECM components, including COL-1, LN and COL-3 in (A) normal ASMCs and (B) ASMCs from rat model of chronic obstructive pulmonary disease using ELISA assay. Data are presented as the mean ± standard deviation in triplicate. \*P\<0.05, \*\*P\<0.01 and \*\*\*P\<0.001 vs. the control group. ECM, extracellular matrix; ASMCs, airway smooth muscle cells; MMP-9, matrix metalloproteinase-9; COL, collagen; LN, laminin; CXCL, C-X-C motif chemokine ligand; IL-6, interleukin-6.](MMR-18-03-3143-g03){#f4-mmr-18-03-3143}

![Effects of ECM components on the downstream molecules in ASMCs. Relative expression of TGFβ1, FGF-1, MMP-9 and TIMP1 was determined in ASMCs following treatment with ECM components, including COL-1, LN and COL-3 by (A) reverse transcription-quantitative polymerase chain reaction and (B) western blotting. Data are presented as the mean ± standard deviation in triplicate. \*P\<0.05 and \*\*P\<0.01 vs. the control group. ECM, extracellular matrix; ASMCs, airway smooth muscle cells; COL, collagen; LN, laminin; TGFβ1, transforming growth factor β-1; FGF-1, fibroblast growth factor-1; MMP-9, matrix metalloproteinase-9; TIMP1, metalloproteinase inhibitor 1; COPD, chronic obstructive pulmonary disease.](MMR-18-03-3143-g04){#f5-mmr-18-03-3143}

![Effects of PI3K/AKT signaling pathway on proliferation and cell cycle progression of ASMCs from rat models of chronic obstructive pulmonary disease. (A) Representative images of ASMCs following treatment with COL-3 and PI3K inhibitor LY294002 or activator IGF1 following double staining with EdU (red) and DAPI (blue) under a fluorescent microscope. (B) Cell cycle distribution analysis was performed in ASMCs following treatment with COL-3 and PI3K inhibitor LY294002 or activator IGF-1. Data are presented as the mean ± standard deviation in triplicate. \*P\<0.05 and \*\*P\<0.01 vs. the control group. PI3K, phosphoinositide 3-kinase; ASMCs, airway smooth muscle cells; COL, collagen; NC, negative control (PBS); IGF-1, insulin-like growth factor I; EdU, 5-ethynyl-2′-deoxyuridine.](MMR-18-03-3143-g05){#f6-mmr-18-03-3143}

![Effects of extracellular matrix components of ASMCs in rat models of chronic obstructive pulmonary disease are mediated by the PI3K/AKT signaling pathway. The wound area was (A) visualized and (B) calculated to evaluate motility of ASMCs following combined treatment with COL-3 and PI3K inhibitor LY294002 or activator IGF1. (C) Western blot analysis of components of the PI3K/AKT signaling pathway in ASMCs following combined treatment with COL-3 and PI3K inhibitor LY294002 or activator IGF1. Data are presented as the mean ± standard deviation in triplicate. \*\*P\<0.01 vs. the control group and ^\#\#^P\<0.01 vs. the IGF1 treatment group. ASMCs, airway smooth muscle cells; COL, collagen; IGF-1, insulin-like growth factor-1; TGFβ1, transforming growth factor β-1; FGF-1, fibroblast growth factor-1; MMP-9, matrix metalloproteinase-9; TIMP1, tissue inhibitors of metalloproteinase-1; PI3K, phosphoinositide 3-kinase; p-, phospho-; mTOR, serine/threonine-protein kinase mTOR.](MMR-18-03-3143-g06){#f7-mmr-18-03-3143}
